1 paper and 0 clinical trials exploring nitrous oxide as a treatment for neuroimaging & brain measures.
Nitrous oxide (N₂O) is a rapid-acting NMDA receptor antagonist with emerging evidence for antidepressant efficacy in treatment-resistant depression. Delivered as a 50% N₂O/50% O₂ inhalation mixture over one-hour sessions, it produces rapid mood improvements that can persist for days to weeks. Its established safety record in anesthesia, short session duration, minimal recovery time, and low cost position it as a potentially scalable alternative to IV ketamine and esketamine, though the psychiatric evidence base remains early-stage and no formal psychiatric indication exists. Key open questions include optimal dosing frequency, long-term durability, and the mechanism by which NMDA antagonism without intense psychedelic phenomenology produces antidepressant effects.
Full Nitrous Oxide profileRecent advances in neuroimaging have shed light on the neurobiological mechanisms underlying the effects of psychedelics, particularly in the treatment of mental health disorders such as depression and PTSD. Studies involving compounds like psilocybin and MDMA have demonstrated significant changes in brain activity associated with therapeutic outcomes.
Full Neuroimaging & Brain Measures profileNo clinical trials have been tagged with both Nitrous Oxide and Neuroimaging & Brain Measures yet.
Trials are continuously being added as new studies are registered.